Cargando…

A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy

Chimeric antigen receptor (CAR) T cells targeting CD19 have been successful treating patients with relapsed/refractory B cell acute lymphoblastic leukemia (ALL) and B cell lymphomas. However, relapse after CAR T cell therapy is still a challenge. In addition, preclinical and early clinical studies t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Epperly, Rebecca, Gottschalk, Stephen, Velasquez, M. Paulina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058784/ https://www.ncbi.nlm.nih.gov/pubmed/32185132 http://dx.doi.org/10.3389/fonc.2020.00262

Ejemplares similares

Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond
por: Epperly, Rebecca, et al.
Publicado: (2020)

Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy
por: Lindo, Lorenzo, et al.
Publicado: (2021)

Infectious Complications in Pediatric, Adolescent and Young Adult Patients Undergoing CD19-CAR T Cell Therapy
por: Maron, Gabriela M., et al.
Publicado: (2022)

More Bumps on the Vaccine Road
por: Dodds, W. Jean
Publicado: (1999)

Extracellular Vesicles and Chemotherapy Resistance in the AML Microenvironment
por: Nehrbas, Jill, et al.
Publicado: (2020)

The Road to CAR T-Cell Therapies for Pediatric CNS Tumors: Obstacles and New Avenues
por: Burns, Ian, et al.
Publicado: (2022)

Maintenance Therapy in AML
por: Reville, Patrick K., et al.
Publicado: (2021)

Unifying heterogeneous expression data to predict targets for CAR-T cell therapy
por: Schreiner, Patrick, et al.
Publicado: (2021)

Putting the Bumps in the Rocky Road: Optimizing the Pathway to Excellence
por: Collins, David J., et al.
Publicado: (2016)

The Black Hole: CAR T Cell Therapy in AML
por: Atilla, Erden, et al.
Publicado: (2023)

Maintenance therapy for AML after allogeneic HCT
por: Nayak, Rahul K., et al.
Publicado: (2022)

Biomarkers as targets for CAR-T/NK cell therapy in AML
por: Shao, Ruonan, et al.
Publicado: (2023)

CAR T Cell Therapy for Pediatric Brain Tumors
por: Patterson, John D., et al.
Publicado: (2020)

Optimal regulation of bipedal walking speed despite an unexpected bump in the road
por: Darici, Osman, et al.
Publicado: (2018)

Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome—A Wandering Road to Remission
por: Wang, Yiyun, et al.
Publicado: (2021)

Chimeric antigen receptor T-cell therapy for T-ALL and AML
por: Wei, Wenwen, et al.
Publicado: (2022)

Coming in from the cold: overcoming the hostile immune microenvironment of medulloblastoma
por: Eisemann, Tanja, et al.
Publicado: (2022)

Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG+ AML
por: Yao, Sun, et al.
Publicado: (2019)

Targeted therapy in NPM1-mutated AML: Knowns and unknowns
por: Wang, Rong, et al.
Publicado: (2022)

CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells
por: Hebbar, Nikhil, et al.
Publicado: (2022)

How globalization became a thing that goes bump in the night
por: Kobrin, Stephen J.
Publicado: (2020)

CD19 CAR T-cell therapy demonstrates activity against extramedullary disease in pediatric patients with B-ALL
por: Epperly, Rebecca, et al.
Publicado: (2023)

Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models
por: Mu-Mosley, Hong, et al.
Publicado: (2022)

A Metabolism Toolbox for CAR T Therapy
por: Xu, Xuequn, et al.
Publicado: (2019)

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
por: Xin, Tianqing, et al.
Publicado: (2022)

Editorial: CAR T-Cell Therapies in Hematologic Tumors
por: Coscia, Marta, et al.
Publicado: (2020)

Strategies for Dodging the Obstacles in CAR T Cell Therapy
por: Safarzadeh Kozani, Pooria, et al.
Publicado: (2021)

Emerging CAR T Cell Strategies for the Treatment of AML
por: Vishwasrao, Paresh, et al.
Publicado: (2022)

MRD Tailored Therapy in AML: What We Have Learned So Far
por: Ngai, Lok Lam, et al.
Publicado: (2021)

Dynamic changes in physical function during intensive chemotherapy affect transplant outcomes in older adults with AML
por: Min, Gi-June, et al.
Publicado: (2023)

The event-driven nature of online political hostility: How offline political events make online interactions more hostile
por: Hebbelstrup Rye Rasmussen, Stig, et al.
Publicado: (2023)

Paraisos hostiles /
por: Aguilera Garramuño, Marco Tulio
Publicado: (1985)

The physiology of hostility
por: Moyer, Kenneth E. (Kenneth Evan), 1919-2006
Publicado: (1971)

CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead
por: Zhang, Qingyang, et al.
Publicado: (2020)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

Targeting CXCR4 in AML and ALL
por: Cancilla, Daniel, et al.
Publicado: (2020)

The Graft-Versus-Leukemia Effect in AML
por: Sweeney, Connor, et al.
Publicado: (2019)

Editorial: The Biological Landscape of Immunotherapy in AML
por: Isidori, Alessandro, et al.
Publicado: (2021)

Editorial: The latest advances in transplantation for AML
por: Chiusolo, Patrizia, et al.
Publicado: (2023)

Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
por: Cheng, Jiali, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_oqrf7mk3rljuuck2dhpsdhv1q4